Pharma Focus Asia
KP - Choose our fully recyclable blister films

Dizal's Golidocitinib New Drug Application Accepted in China

Friday, September 15, 2023

Dizal has announced that the Centre for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for golidocitinib for the treatment of relapsed or refractory peripheral T-cell lymphoma (r/r PTCL). 

Golidocitinib, as a first-in-class JAK1-only inhibitor, has demonstrated a superior efficacy and safety profile, offering a much-needed treatment option for patients with this challenging disease.

The JAK/STAT signaling pathway is crucial in the development and advancement of several hematologic malignancies, including T-cell malignancies. Golidocitinib, is currently the only inhibitor in the NDA stage for r/r PTCL, demonstrating considerable promise in restraining tumor growth and proliferation through its precise targeting of the JAK/STAT pathway.

Golidocitinib has demonstrated robust and durable anti- tumour activity, as evidenced by an objective response rate (ORR) of 44.3 percent and a complete response rate (CRR) of 23.9 percent. 

These findings indicate that golidocitinib holds substantial promise as an innovative and effective therapeutic option for individuals battling relapsed or refractory peripheral T-cell lymphoma, potentially offering an improved outcomes and hope for better quality of life.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® products5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024